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ABSTRACT
Introduction: This study aimed to isolate and identify Candida spp. from the environment, 
health practitioners, and patients with the presumptive diagnosis of candidiasis in the Pediatric 
Unit at the Universitary Hospital of the Jundiaí Medical College, to verify the production of 
enzymes regarded as virulence factors, and to determine how susceptible the isolated samples 
from patients with candidiasis are to antifungal agents. Methods: Between March and November 
of 2008 a total of 283 samples were taken randomly from the environment and from the hands 
of health staff, and samples of all the suspected cases of Candida spp. hospital-acquired infection 
were collected and selected by the Infection Control Committee. The material was processed 
and the yeast genus Candida was isolated and identified by physiological, microscopic, and 
macroscopic attributes. Results: The incidence of Candida spp. in the environment and employees 
was 19.2%. The most frequent species were C. parapsilosis and C. tropicalis among the workers, 
C. guilliermondii and C. tropicalis in the air, C. lusitanae on the contact surfaces, and C. tropicalis 
and C. guilliermondii in the climate control equipment. The college hospital had 320 admissions, 
of which 13 (4%) presented Candida spp. infections; three of them died, two being victims of 
a C. tropicalis infection and the remaining one of C. albicans. All the Candida spp. in the isolates 
evidenced sensitivity to amphotericin B, nystatin, and fluconazole. Conclusions: The increase in 
the rate of hospital-acquired infections caused by Candida spp. indicates the need to take larger 
measures regarding recurrent control of the environment.
Keywords: Candidemia. Neonatal Intensive Care Unit. Nosocomial infection. Pediatric 
Intensive Care Unit.
RESUMO
Introdução: Isolar e identificar Candida spp. do ambiente, dos profissionais de saúde e de 
pacientes com diagnóstico presuntivo de candidíase, em Unidade de Pediatria do Hospital 
Universitário da Faculdade de Medicina de Jundiaí, verificar a produção de enzimas consideradas 
fatores de virulência e identificar a resistência das cepas isoladas dos pacientes aos antifúngicos. 
Métodos: Foram feitas 283 coletas no período entre março e novembro de 2008 de forma 
randomizada do ambiente, das mãos de profissionais de saúde e de todos os pacientes com casos 
suspeitos de infecção hospitalar por Candida spp., triados pelo Comitê de Infecção Hospitalar. 
Todo o material coletado foi processado e as leveduras do gênero Candida foram isoladas e 
identificadas pelas características macroscópicas, microscópicas e fisiológicas. Resultados: 
A incidência de Candida spp. no meio-ambiente e funcionários foi de 19,2%. Destes, as espécies 
mais frequentes entre os funcionários foram C. parapsilosis e C. tropicalis; no ar ambiente, 
C. guilliermondii e C. tropicalis; nas superfícies dos ambientes, C. lusitanae e nos sistemas de 
climatização, C. tropicalis e C. guilliermondii. No período de estudo, foram feitas 320 internações, e 
13 (4%) apresentaram infecção hospitalar por Candida spp, sendo que 3 pacientes foram a óbito, 
dois apresentando infecção por C. tropicalis e um por C. albicans. Todas as espécies de Candida 
spp. isoladas dos pacientes foram sensíveis à anfotericina B, nistatina e fluconazol. Conclusões: 
Verificamos um aumento crescente de infecções hospitalares por Candida não albicans, o que 
sugere a necessidade de maiores precauções em relação a um controle ambiental destas espécies.
Palavras-chaves: Candidemia. Unidade Neonatal de Terapia Intensiva. Infecção hospitalar. 
Unidade Pediátrica de Terapia Itensiva.
An increasing number of fungal infections 
have been detected on a global level. This raises 
an important matter of public health1, as it makes 
hospital stays longer2 and stands as relevant cause 
of morbidity and mortality among patients2-9. The 
mortality rate associated with Candidemia in the 
United States has recently been estimated at 49%1, a 
rate that may reach 75% in neonatal intensive care 
units (NICU)5, while the expenses attributed to an 
episode of invasive candidiasis are estimated at 
approximately $28,000 and $48,000 for pediatric 
and adult patients, respectively1.
In the last 20 years, the whole world has seen a 
meaningful increase in infections caused by Candida spp., 
especially in intensive care units (ICU)2,10; the 
main risk factors have been established, namely, low 
weight, preterm birth, immunological deficiency, 
congenital disorders, use of third-generation 
cephalosporins, invasive routine procedures, use 
of vascular catheters, and a long period of hospital 
ingression3-5,8. Candida albicans is the species that 
mainly causes nosocomial infections, although 
some non-albicans species are also reported as causal 
agents2,3,9. Among the most recurrent species of 
Candida non-albicans, C. tropicalis, C. parapsilosis, 
C. krusei, and C. glabrata find more prominence. In 
the 1980s, C. albicans used to be the most frequent 
pathogen of nosocomial bloodstream infections, and 
since the 1990s its yeasts have become the third main 
cause of hospital-acquired infections8,10. 
Nosocomial fungal infections may have their 
origin in endogenous strains (introduced into the 
hospital by the patients themselves) or in exogenous 
sources, transmitted to patients via contaminated 
infusions, biomedical devices, or even by the hands 
of the hospital staff members1,3,11,12. Besides, it has 
been noticed that constant contact with patients in a 
hospital environment facilitates cross-contamination 
inside the ICU1,2,3,8,11,12. Considering the relevance of 
Candida spp. as infectious agents in dissemination, 
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the diversity of such species, and the occurrence of strains that 
can resist the main antifungal agents, the aims of this study were 
to isolate and identify the Candida spp. in the environment, 
health professionals, and patients with the presumptive diagnosis 
of candidiasis in the pediatric unit at the hospital in the Jundiaí 
Medical College; to verify the production of enzymes regarded as 
virulence factors (phospholipase and proteinase); and to identify 
how susceptible the isolated samples from patients with candidiasis 
are to antifungal agents.
This research was developed at the hospital associated with the 
Medical College of Jundiaí and integrated into the Single Health 
System (SUS, in Portuguese) in the City of Jundiaí, State of São 
Paulo, Brazil. The hospital stands on the intermediate level of care 
and allocates 62 beds, consisting of 13 in the NICU, 19 in the semi-
NICU and late admission wards, 6 in the pediatric intensive care unit 
(PICU), and 24 pediatric beds, which earns it the title of third-level 
medium-sized hospital. The hospital staff comprises 30 physicians 
and 40 nurses at the NICU and semi-NICU, 14 physicians on duty, 
34 nurses at the pediatric ward and PICU, and 10 resident physicians.
From March to November 2008, monthly random samples were 
collected from the hospital air and staff in the following manner: 
108 samples from the hospital staff (doctors, nurses, and healthcare 
assistants), 72 samples from room air (pediatric ward rooms, toy 
room, operating room, NICU, and  PICU), 63 from contact surfaces 
in the toy room and from the NICU and PICU (door handles, light 
switches, counters, chairs, toys, remote controls), and 27 from the 
water-collection trays in the climate control equipment.
Air samples were collected through the technique of Sabouraud 
dextrose agar plate preparation (DIFCO™) and CHROMagar 
Candida (Microbiology™). The samples were exposed to the 
environment for 30min and kept in a stove at 37°C for 96h13.
The samples from contact surfaces were collected by sterile swab 
suspension in 1ml of saline solution rubbed on a 5cm² area of walls, 
toys, and trays in the climate control equipment. The same method 
was employed in collecting the samples from the hospital staff, 
by rubbing the sterile swab on the hands and nails. The collected 
material was immediately processed in the lab through the culture 
of Sabouraud dextrose agar plates and CHROMagar and was 
maintained in a stove at 37°C for 96h.
All the suspected cases of hospital-acquired invasive candidiasis 
were selected by the Infection Control Committee during the period 
of this study. Samples were collected and immediately sent to the 
laboratory for identification.
The isolated yeasts were identified by physiological, microscopic, 
and macroscopic attributes, following the methodology supported 
by Kurtzman and Fell14. 
The proteinase secretion of the isolated Candida species was 
tested through the procedure described by Ruchel et al.15, and the 
phospholipase activity was tested according to Price et al.16; the 
activity rate of those enzymes (Pz) was achieved by following Price 
et al., and the samples considered as positive were those revealing 
Pz < 1.016.
The Candida spp. isolates from patients were submitted to 
susceptibility testing via disk diffusion antibiotic sensitivity testing. 
The isolates had been previously grown in Sabouraud dextrose agar 
(DIFCO™) at 37°C for 24h; after this culture, the isolates experienced 
suspension in sterile saline solution to 0.5 McFarland scale. With 
a sterile swab, the inoculum was spread on Muller Hinton agar 
(DIFCO™), supplemented with 2% of glucose and 0.5ug/ml of 
methylene blue. Disks of amphotericin B, fluconazole, econazole, 
itraconazole, 5-fluorocytosine, and ketoconazole were also employed. 
The plates were incubated in a stove at 37°C for 24h. The results 
were interpreted as sensitive (S), intermediate (I), or resistant (R), 
following the instructions given by the manufacturer (CECON™).
The associations were statistically evaluated by Fisher’s exact test 
(significance level 5%) and SAS software version 9.1.3.
Ethical considerations
The protocol was conducted following the ethical principles 
established in the Declaration of Helsinki proposed by the World 
Medical Association (Declaration of Helsinki, 1964, 1975, 1983, 
1989, 1996, 2000). The project was submitted for approval by the 
Ethics Committee in Research of the Jundiaí Medical College. 
All participants were informed about the project and degree of 
involvement in it, and were asked to sign the Instrument of Consent 
(Ministry of Health/National Health Foundation, 1996), consisting 
of clarification regarding the following aspects: I) justification, 
objectives, and procedures used; II) discomfort, potential risks, and 
expected benefits; III) a follow-up and assistance and their respective 
officers; IV) the freedom to refuse to participate or withdraw their 
consent at any stage of the research without penalty or loss; and vi) 
assurance of confidentiality regarding the data collected.
During the study, a total of 270 sample involving both the 
environment and its workers were collected, and Candida spp. were 
isolated in 52 (19.2%) of these samples. The species C. albicans was 
isolated only once, from a healthcare assistant. Considering all the 
other places, only Candida non-albicans species were isolated. The 
largest isolation rate happened in the system of climate control 
(33.3%), followed by the contact surfaces (23.8%), staff (15.7%), 
and room air (15.3%) (Table 1).
Considering the members of the hospital staff, the largest 
isolation rate occurred among the healthcare assistants (20.4%), and 
the single room-air isolation was from the toys room. In relation to 
the contact surfaces analyzed and the climate control system, the 
largest rates occurred at the PICU at 44.4% and 66.7%, respectively. 
No isolation was obtained from the climate control equipment in 
the operating room (Table 1). 
In view of the isolated species, the most frequent was C. tropicalis 
(27.4%), followed by C. guilliermondii (23.5%), C. parapsilosis 
(19,6%), C. lusitanae (17.6%), and C. krusei (11.8%) (Table 2).
The most frequent species were C. parapsilosis and C. tropicalis 
among the hospital employees, C. guilliermondii and C. tropicalis in 
the room air, C. lusitanae on the contact surfaces, and C. tropicalis and 
C. guilliermondii in the climate control devices (Table 2). 
During this research, the hospital attended to 320 ingressions, 
of which 13 (4%) revealed hospital-acquired infections by Candida 
spp. (invasive candidiasis); 5 of these patients were staying at the 
NICU and 8 at the PICU. 
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TABLE 1 - Frequency of Candida albicans and Candida non-albicans in 270 
samples from The environment and staff at the Universitary Hospital of the 
Jundiaí Medical College, State of São Paulo, Brazil, from March to November 2008.
 Collected  Candida  Candida  Frequency
 samples (n) albicans non- albicans (%)
Workers     
physicians 27 0 4 14.8
nurses 27 0 2 7.4
healthcare assistants  54 1 10 20.4
Total 108 1 16 15.7
Room air    
rooms 27 0 5 18.5
toy room 9 0 0 0.0
ICUs and operating room 36 0 6 16.7
Total 72 0 11 15.3
Contact surface    
toy room 36 0 9 25.0
NICU 18 0 2 11.1
PICU 9 0 4 44.4
Total 63 0 15 23.8
Climate control system    
PICU 9 0 6 66.7
NICU 9 0 3 33.3
operating room 9 0 0 0.0
Total 27 0 9 33.3
Sum total  270 1 51 19.3
ICUs: intensive care units; PICU: pediatric intensive care unit; NICU: neonatal 
intensive care unit. 
TABLE 2 - Incidence of Candida non-albicans species in 51 isolates from the 
environment and staff at the Universitary Hospital of the Jundiaí Medical College, State 
of São Paulo, Brazil, from March to November 2008.
                                  Candida  
 tropicalis parapsilosis krusei lusitaneae guilliermondii
Workers      
physicians 1 1 2 0 0
nurses 1 1 0 0 0
healthcare assistants  3 4 1 0 2
Total 5 6 3 0 2
Room air     
rooms 3 1 0 1 0
toy room 0 0 0 0 0
ICUs and operating room 1 0 0 0 5
Total 4 1 0 1 5
Contact surface     
toy room 0 1 2 6 0
NICU 0 1 0 0 1
PICU 1 1 1 1 0
Total 1 3 3 7 1
Climate control system     
PICU 3 0 0 0 3
NICU 1 0 0 1 1
operating room 0 0 0 0 0
Total 4 0 0 1 4
Sum Total  14 10 6 9 12
ICUs: intensive care units; PICU: pediatric intensive care unit; NICU: neonatal intensive 
care unit. 
TABLE 3 - Hospital-acquired infection by Candida spp. detected in 13 patients 
in the NICU and PICU at the Hospital of the Jundiaí Medical College, State of 
São Paulo, Brazil, from March to November 2008.
                                                                                                                                                   Cases
Species n %
Candida albicans 7 53.8
Candida tropicalis 3 23.1
Candida parapsilosis 1 7.7
Candida krusei 1 7.7
Candida guilliermondii 1 7.7
PICU: pediatric intensive care unit; NICU: neonatal intensive care unit. 
TABLE 4 - Antifungal susceptibility testing of Candida spp. isolates from 13 patients in the NICU and PICU at the hospital of the 
Jundiaí Medical College, State of São Paulo, Brazil, from March to November 2008.
 Samples Amphotericin B Econazole Nystatin Ketoconazole Itraconazole Fluconazole
Species of Candida n S S I R S S I S I S
albicans 7 7 5 1 1 7 3 4 7 0 7
tropicalis 3 3 2 1 0 3 3 0 2 1 3
parapsilosis 1 1 1 0 0 1 1 0 1 0 1
krusei 1 1 1 0 0 1 1 0 0 1 1
guillermondii 1 1 1 0 0 1 1 0 1 0 1
PICU: pediatric intensive care unit; NICU: neonatal intensive care unit; S: sensitive; I: intermediate; R: resistant.
Seven of the 13 cases presented C. albicans infection; 3 were 
C. tropicalis, 1 C. parapsilosis, 1 C. krusei, and 1 C. guilliermondii 
(Table 3). The isolates of Candida spp. from the infections were 
obtained through blood culture (9 of the cases) and urine culture 
(4 of the cases). Three patients died. Two of them were inpatients 
at the NICU, with one infected by C. albicans and the other by 
C. tropicalis; the third patient who died was at the PICU and presented 
an infection by C. tropicalis. 
All the Candida spp. isolated from the patients were sensitive to 
amphotericin B, nystatin, and fluconazole. In relation to econazole 
and itraconazole, some samples presented intermediate susceptibility, 
but only one sample of C. albicans was resistant to econazole 
(Table 4).
To calculate the enzyme activity of proteinase and phospholipase, 
the Pz value was applied according to Price et al., with isolates 
with Pz < 1.0 considered as positive. Considering the 8 C. albicans 
isolates, 87.5% were regarded as positive for phospholipase activity, 
whereas only 8.8% of the Candida non-albicans presented positivity. 
In the light of the proteinase, only 12.5% of C. albicans and 21.1% 
of Candida non-albicans were positive, presenting no significant 
differences among the isolates from the range of groups. In relation 
to phospholipase activity in the patients’ isolates, a relevant difference 
was observed between the C. albicans and Candida non-albicans 
isolates (Table 5).
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TABLE 5 - Positivity of proteinase and phospholipase activities (Price et al., 
1982) in Candida albicans and Candida non-albicans isolates from patients 
and environment at the Hospital of the Jundiaí Medical College, State of São 
Paulo, Brazil SP, from March to November 2008.
 Number of  Isolations 
 patients  environment Total
Candida albicans 7 1 8
Proteinase activity (n/%) 1/14.3 0/0.0 1/12.5
Phospholipase activity (n/%) 6/85.7* 1/100.0 7/87.5
Candida non-albicans/number of isolations 6 51 57
Proteinase activity (n/%) 1/16.7 11/21.5 12/21.1
Phospholipase activity (n/%) 1/16.7* 4/7.8 5/8.8
*statistically significant difference p>0.05.
Nosocomial infections caused by Candida spp. currently 
represent a serious matter for the public health, since the rates 
of incidence and mortality associated with these infections have 
revealed a considerable increase in third-level hospitals during the 
last decades17-19. Species of the genus Candida have been the most 
frequently isolated agents, which correspond to approximately 80% 
of the hospital-acquired fungal infections that cause death to 12% to 
60% of the patients who develop candidemia19-21.
The occurrence of nosocomial infections by invasive candidiasis 
at the Universitary Hospital of the Jundiaí Medical College during 
the period covered by this research was of 4% above the average 
described by national and international references, which report an 
occurrence rate of 1.49 to 6.6 cases in 1,000 hospital admissions22-26.
The hospital sector where cases of candidemia are most 
commonly found is the ICU, for besides being the place where 
patients find themselves more impaired, it also completes a routine 
of invasive procedures, probes, and long-term catheters19,27-29. All the 
candidemia cases in this study were observed in patients in ICUs, 
a point that is also discussed by other studies that recognize the 
ICU as a place of utmost susceptibility to the incidence of such 
infection30-33.
The absolute mortality rate due to candidemia was 23.1%, a result 
that is also consonant with the data provided by the bibliographic 
references18-20. Two of the patients who died were immunosuppressive 
newborns; they were in the NICU, and they acquired sepsis. The third 
patient who died was a 7-year-old child who had heart co-morbidity 
and was settled in the PICU. The two Candida species responsible 
for these mortality cases were C. albicans and C. tropicalis.
Candida albicans was the species most frequently found among 
patients (53.8%), corroborating what other studies have been 
demonstrating in different anatomical sites19,30,31,34,35.
On the other hand, many researches have exposed the last 
decades’ increase of infections as caused by other species of 
Candida2,3,18,19,30,31. This point was also verified in our study, which 
showed the relevance of identifying different Candida spp., aimed 
at gaining better epidemiological knowledge about the disease and 
its usual resistance to therapy, typical of the Candida non-albicans 
species that not only make the treatment difficult and expensive, but 
also provide an inaccurate prognostic36.
Among the Candida non-albicans species, the most recurring 
one was C. tropicalis (23.1%), which along with C. albicans accounts 
for 76.9% of the candidemia cases and stands as the second most 
common pathogen, a fact that was already noticed in another work37. 
Fifty percent to 60% of the patients who present this species are 
expected to develop systemic infections38. Other studies point to 
C. parapsilosis as the most prevalent species among the Candida 
non-albicans1-4,18,24,34,35,39. In pediatric or neonatal units, C. parapsilosis 
has been marked as the second most common agent in patients with 
candidemia, a fact that is linked to the exogenous contamination 
because of the patients’ manipulation by the hospital staff, the 
patients’ exposure to invasive procedures in the ICU, prematurity, 
immunosuppression, and long-course antibiotic therapy34,35,39-41. 
Results from many other works have evidenced C. tropicalis or 
C. parapsilosis as the main Candida non-albicans agent involved in 
the different types of candidemia around us38,42-47, which is different 
from what has been observed in Europe and North America, 
where C. glabrata has been detected as the second most recurrent 
pathogen after C. albicans43,44,47-49. This species was not isolated in 
our research. 
Displaying an inferior occurrence that represents 23.1% of the 
remaining candidemia cases, C. parapsilosis (7.7%), C. krusei (7.7%), 
and C. guilliermondii (7.7%) were also identified in this study.
In relation to the samples isolated from the room air and 
the staff, the Candida non-albicans species were predominant 
and represented by C. tropicalis, C. parapsilosis, C. guilliermondii, 
C. lusitaneae, and C. krusei, a fact that confirms what other studies 
have demonstrated2,24,50,51. With reference to health practitioners, 
some researches inform that C. albicans is the most commonly 
isolated species from the hands of the healthcare staff51,52, while some 
authors have identified C. tropicalis and C. parapsilosis as dominant 
species2,12,24,50,51. In this work, C. albicans was isolated only once 
from the hand of a healthcare assistant; it was never isolated from 
the room air.
The incidence of Candida spp. among the workers was 15.7%, 
an average that is below the result previously verified by other 
studies52,53. However, except for C. lusitaneae, which was not isolated 
from any patient in this research, the remaining isolates of Candida 
non-albicans from the environment and the hands of the hospital 
staff members were also isolated from the patients. This fact might 
indicate an exogenous transmission via direct contact, which makes 
necessary a number of comparative molecular studies to confirm 
this hypothesis. Although most candidemia cases occur because of 
a pre-existent colonization in the patient (by the same species of 
yeast that causes the infection), hematopoietic infections of difficult 
control may also be acquired through manipulation and direct contact 
made by the hands of healthcare professionals54-58.
There was a correlation between the incidence of C. tropicalis and 
C. guilliermondii, the room air, and the trays in the climate control 
equipment: all the Candida spp. samples from these places were 
Candida non-albicans, with a positivity rate of 15.3% in the room 
air and 33.3% in the climate control system. In view of the results, it 
is not possible to state that the same species detected in the climate 
control system were responsible for contamination and migration 
to the room air, since the operating room did not have Candida spp. 
positive in its climate control equipment, although C. guilliermondii 
actually had a positive detection in the room air. Nevertheless, both 
the climate control system and the room air in the PICU presented 
C. guilliermondii positivity, which might imply a yeast migration 
through the climate control system.
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Considering the total samples collected from the furniture 
surface, 23.8% were positive for Candida spp., all of them being 
Candida non-albicans, with a prevalence of C. lusitaneae, which differs 
from a similar study that found a dominance of C. guilliermondii on 
the surface of the hospital furniture51.
The Candida non-albicans isolates verified in this range of sectors, 
plus the growing increase in hospital-acquired infections caused by 
these species observed in recent years, suggest the importance of 
being attentive to frequent control of environment. A number of 
works have implied that the proteinase and phospholipase enzymes 
might be virulence factors of Candida spp59-62.
In relation to proteinase, there was no significant difference in the 
production of this enzyme between C. albicans and the Candida non-
albicans isolated from patients, corresponding to 14.3% and 16.7% 
of the samples, respectively. It is important to note that 21.5% of the 
Candida non-albicans samples isolated from the environment showed 
proteinase activity. Other studies demonstrate a larger incidence of 
proteinase production by Candida non-albicans species25,29,59,60.
On the other hand, 85.7% of the C. albicans samples isolated 
from patients were positive for phospholipase activity, whereas only 
16.7% of the Candida non-albicans revealed phospholipase positivity, 
suggesting that this enzyme and C. albicans might be associated 
but are independent of virulence, as confirmed by other works 
that attest to the predominant production of phospholipase among 
C. albicans isolates from both healthy individuals and pathogenic cases, 
proving that phospholipase synthesis is not restricted to pathogenic 
samples24,28,36,46,52,58. Such fact also implies that phospholipase is not a 
determinant factor of the disease settlement, once the host immunity, 
the endogenous presence of C. albicans, and the effectiveness of the 
pathogenicity in the samples are also considered.
Other studies demonstrate that pathogenic samples produce 
more proteinase than phospholipase47,53,59,60,63. However, this is a 
controversial statement, and this discussion concerning enzyme 
activity as a virulence factor of Candida spp. remains unresolved.
Analysis of the antifungal susceptibility testing of Candida spp. 
isolates from pediatric patients showed all the samples to be in vitro 
sensitive to the main treatment drugs used in our hospital, fluconazole 
and amphotericin B. Nevertheless, there are several divergences 
concerning the resistance to antifungal therapies, especially among 
the Candida non-albicans species, which have presented resistance to 
the treatment elected in different parts of the world2,4,8,9,64,65.
The treatment accomplished in our work was satisfactory and is 
according to the reality in most public hospitals in Brazil, where the 
first-choice drug for candidemia is fluconazole22. However, there is a 
new therapeutic class of antifungal drugs for invasive candidiasis. This 
class is known as the echinocandins, which are showing to be more 
safe and effective and with fewer side effects than the other drugs; 
they can be used as an excellent therapeutic option, especially in cases 
of recent history of exposure to an azole, moderately severe to severe 
illness (i.e., hemodynamically unstable), and allergy or intolerance 
to azoles66-71. Although amphotericin B remains a therapeutic option 
because of its broad spectrum and low cost, it produces side effects 
related to infusion and nephrotoxicity71-73. Thus, it is only used in case 
of microorganisms that are resistant to azoles and echinocandins and 
in patients who have an intolerance to these drugs, because their use 
may become more expensive and prolong hospital stay73.
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